Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 20/20 | 0.75 |
| ▸ | MAPT | P10636 | 11/20 | 0.75 |
| ▸ | GSK3B | P49841 | 4/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20199750 | 0.86 | GSK3A (1.00) | GSK3AMAPTGSK3BPIM1CDK2 | |
| SCHEMBL21331456 | 0.83 | GSK3A (0.78) | GSK3AMAPTGSK3BPIM1CDK2 | |
| SCHEMBL20199584 | 0.82 | GSK3A (1.00) | GSK3AMAPTGSK3BPIM1CDK2 | |
| SCHEMBL20199414 | 0.81 | GSK3A (0.75) | GSK3AMAPTGSK3BPIM1CDK2 | |
| SCHEMBL30052026 | 0.79 | GSK3A (0.73) | GSK3AMAPTGSK3BPIM1CDK2 | |
| SCHEMBL20199419 | 0.79 | GSK3A (0.73) | GSK3AMAPTGSK3BPIM1CDK2 | |
| SCHEMBL20199477 | 0.78 | GSK3A (1.00) | GSK3AMAPTGSK3B | |
| SCHEMBL20199410 | 0.77 | GSK3A (1.00) | GSK3AMAPTGSK3BPIM1CDK2 | |
| SCHEMBL30050892 | 0.77 | GSK3A (1.00) | GSK3AMAPTGSK3BPIM1CDK2 | |
| SCHEMBL20199390 | 0.76 | GSK3A (0.90) | GSK3AMAPTGSK3BPIM1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544980-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3544980-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10774086-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774086-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018098411-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276463-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | GSK3A 2/4885MAPT 81/4885GSK3B 1/4885 |
| US-10774086-B2 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3A 2/4885MAPT 81/4885GSK3B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.